|
Market Closed -
NYSE
04:00:00 2026-09-03 pm EDT
|
5-day change | 1st Jan Change | ||
| 2.620 USD | +1.16% |
|
+0.38% | +45.56% |
Company Valuation: Protalix BioTherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 211.1 | - | - |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 45.83% | - | - |
| Enterprise Value (EV) | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 211.1 | 211.1 | 211.1 |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 45.83% | 0% | 0% |
| P/E | -1.34x | -4.42x | 19.8x | 47x | -22.5x | 13.8x | 47.6x | 131x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | -0.8x | 0x | -0x | -0.7x | -2.1x |
| Capitalization / Revenue | 0.99x | 1.46x | 1.98x | 2.59x | 2.74x | 2.65x | 3.1x | 3.07x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.65x | 3.1x | 3.07x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | 0x | -0x | 11.5x | 62.5x | 187x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.62 | -0.31 | 0.09 | 0.04 | -0.08 | 0.19 | 0.055 | 0.02 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.35 | 47.64 | 65.49 | 53.4 | 52.74 | 79.8 | 68.19 | 68.82 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.46 | -13.01 | 10.46 | 3.917 | -5.5 | 18.35 | 3.378 | 1.131 |
| Net income 1 | -27.58 | -14.93 | 8.312 | 2.932 | -6.604 | 15.38 | 4.463 | 1.518 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.832 | 1.370 | 1.780 | 1.880 | 1.800 | 2.620 | 2.620 | 2.620 |
| Nbr of stocks (in thousands) | 45,557 | 50,666 | 72,952 | 73,634 | 80,421 | 80,572 | - | - |
| Announcement Date | 3/31/22 | 2/27/23 | 3/14/24 | 3/17/25 | 3/18/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 13.63x | - | - | - | 209M | |
| 33.02x | 11.99x | 24.32x | 0.6% | 1,034B | |
| 30.61x | - | - | 1.95% | 663B | |
| 33.41x | 7.74x | 16.08x | 2.62% | 462B | |
| 19.46x | 4.63x | 11.48x | 2.86% | 344B | |
| 22.94x | 5.89x | 14.62x | 2.7% | 307B | |
| 20.8x | 4.27x | 12.2x | 2.06% | 251B | |
| 28.01x | 7.21x | 12.82x | 2.28% | 239B | |
| 13.44x | 4.86x | 10.14x | 3.75% | 207B | |
| -45.71x | 6.59x | 25.73x | 2.2% | 186B | |
| Average | 16.96x | 6.65x | 15.92x | 2.34% | 369.36B | |
| Weighted average by Cap. | 24.33x | 8.05x | 17.83x | 1.95% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PLX Stock
- Valuation Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
